Research Summary
Dr. Luo’s research focuses on genomic studies of prostate cancer. His research interests include the discovery, validation and application of molecular determinants and indicators of prostate cancer progression in various treatment settings. He is also interested in prostate tumor biology and genomic research to explain the substantial variation in prostate cancer incidence and mortality rates among different geographic regions and racial/ethnic groups.
Selected Publications
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England journal of medicine. 2014;371(11):1028-38. Epub 2014/09/04. doi: 10.1056/NEJMoa1315815. PubMed PMID: 25184630.
Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2014. Epub 2014/05/20. doi: 10.1038/onc.2014.115. PubMed PMID: 24837363.
Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Hormones & cancer. 2014;5(5):265-73. Epub 2014/07/23. doi: 10.1007/s12672-014-0190-1. PubMed PMID: 25048254; PubMed Central PMCID: PMC4167475.
Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. Journal of cellular biochemistry. 2014;115(9):1505-15. Epub 2014/03/08. doi: 10.1002/jcb.24805. PubMed PMID: 24604720.
Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Science translational medicine. 2013;5(169):169ra10. Epub 2013/01/25. doi: 10.1126/scitranslmed.3005211. PubMed PMID: 23345608; PubMed Central PMCID: PMC3577373.
Patents
Composition and methods for treating and preventing prostate cancer and for detecting androgen receptor variants.
Patent # P10305-02 |
Methods of detecting prostate cancer.
Patent # 60/959,954 |